Use of Moderate ‐Intensity Statins for Low‐Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in Koreans
Abstract
The ACC/AHA 2013 guideline recommends high‐intensity statin therapy for a decrease in low‐density lipoprotein cholesterol (LDL‐C) level by >50% among patients with baseline values of ≥190 mg/dL (approximately 4.872 mmol/L); however, this value should be modified before applying it to Korean populations. We investigated the statin‐specific LDL‐C‐lowering effects in Korean patients with baseline LDL‐C value ≥4.872 mmol/L. Data of patients prescribed a statin for the first time from January 2009 to December 2013 were assessed. In patients with baseline LDL‐C value ≥4.872 mmol/L, laboratory data for a maximum of 6 months from the date of first statin prescription were collected. Among 33,721 patients who were prescribed a statin for the first time, 655 patients had a baseline LDL‐C value ≥4.872 mmol/L (1.9%). Of these, 179 patients were analysed. Patients receiving moderate‐intensity statins were divided into two groups based on LDL‐C reduction rate (p = 0.0002), defined as moderate–high‐intensity (atorvastatin 20 mg, rosuvastatin 10 mg, simvastatin 20 mg) and moderate–low‐intensity (atorvastatin 10 mg, pitavastatin 2 mg, pravastatin 40 mg) statin groups. LDL‐C reduction rates did not significantly differ between the moderate–high‐ and high‐intensity statin groups (p = 0.4895). We found that some moderate‐intensity statins demonstrated a LDL‐C‐lowering effect of more than 50% in Korean patients with a...
Source: Basic and Clinical Pharmacology and Toxicology - Category: Drugs & Pharmacology Authors: Hun ‐Sung Kim, Hyeseon Lee, Sue Hyun Lee, Yoo Jin Jeong, Tong Min Kim, So Jung Yang, Sun Jung Baik, Hyunah Kim, Seung‐Hwan Lee, Jae Hyoung Cho, In‐Young Choi, Kun‐Ho Yoon, Ju Han Kim Tags: Original Article Source Type: research
More News: Atorvastatin Calcium | Cholesterol | Crestor | Drugs & Pharmacology | Laboratory Medicine | Lipitor | Pravastatin | Rosuvastatin | Simvastatin | Statin Therapy | Toxicology | Zivast | Zocor